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Abstract: Stroke affects one in every six people worldwide, and is the leading cause of adult 
disability. Some spontaneous recovery is usual but of limited extent, and the mechanisms of 
late recovery are not completely understood. Endogenous neurogenesis in humans is thought 
to contribute to repair, but its extent is unknown. Exogenous cell therapy is promising as a 
means of augmenting brain repair, with evidence in animal stroke models of cell migration, 
survival, and differentiation, enhanced endogenous angiogenesis and neurogenesis, immu-
nomodulation, and the secretion of trophic factors by stem cells from a variety of sources, 
but the potential mechanisms of action are incompletely understood. In the animal models of 
stroke, both mesenchymal stem cells (MSCs) and neural stem cells (NSCs) improve functional 
recovery, and MSCs reduce the infarct volume when administered acutely, but the hetero-
geneity in the choice of assessment scales, publication bias, and the possible confounding 
effects of immunosuppressants make the comparison of effects across cell types difficult. 
The use of adult-derived cells avoids the ethical issues around embryonic cells but may have 
more restricted differentiation potential. The use of autologous cells avoids rejection risk, 
but the sources are restricted, and culture expansion may be necessary, delaying treatment. 
Allogeneic cells offer controlled cell numbers and immediate availability, which may have 
advantages for acute treatment. Early clinical trials of both NSCs and MSCs are ongoing, 
and clinical safety data are emerging from limited numbers of selected patients. Ongoing 
research to identify prognostic imaging markers may help to improve patient selection, and 
the novel imaging techniques may identify biomarkers of recovery and the mechanism of 
action for cell therapies.
Keywords: stroke, cerebrovascular disease, cell therapy, neurological disease
Introduction
Stroke is the most common cause of adult-acquired disability in the developed1 
and developing world.2 With an aging population, the incidence and prevalence 
of stroke are predicted to rise.3 Stroke is an acute-onset clinical syndrome that 
develops following a vascular insult to the brain. Brain ischemia resulting from 
thromboembolism or less frequently, in situ thrombosis, constitutes 80%−85%, 
and hemorrhage resulting from hypertension or vessel wall pathology constitutes 
15%−20% of all strokes.  Following vascular occlusion, a complex chain of events 
occurs at a molecular level, leading to irreversible tissue injury, including failure of 
energy synthesis, loss of transmembrane ionic gradients dependent on active trans-
port, cell depolarization, and excitotoxicity due to the excess release of excitatory 
neurotransmitters. In the region with severely reduced blood flow (the ischemic 
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core), these processes result in rapid cell necrosis affecting 
all the cellular elements (neurons, glia, and blood vessels). 
A region around the core (the ischemic penumbra) tran-
siently maintains a collateral blood supply sufficient for 
cell viability. Restoring perfusion can salvage penumbral 
tissue, and timely recanalization is the most robust predic-
tor of good clinical prognosis following ischemic stroke.4 
Early thrombolysis with intravenous recombinant tissue 
plasminogen activator increases the likelihood of recanali-
zation and a recovery to independence defined on scales of 
disability and handicap.5 Alternative reperfusion strategies 
have not yet shown benefit. Secondary processes following 
ischemic injury and cell necrosis include an inflammatory 
response, with the activation of microglia, infiltration of 
tissue by neutrophils and macrophages from the blood, and 
blood−brain barrier breakdown. Inflammatory mediators 
can act as chemoattractants for both the endogenous and 
exogenous cells involved in tissue repair. At the network 
level, regions of the brain that were previously connected to 
the infarcted area reorganize, at least in terms of the brain 
activation patterns seen on functional magnetic resonance 
imaging (fMRI). Rehabilitation exploits the combination of 
functional reorganization and adaptation after stroke.6
Immediately after stroke, several events, including edema, 
deafferentation, and inflammation, occur around the infarct, 
and some early functional recovery can be attributed to the 
resolution of edema and inflammation. However, this is 
usually limited, and other processes, including immuno-
modulation, angiogenesis, endogenous neurogenesis, and 
altered gene expression, may be involved in the longer-term 
recovery of function. The apparent translational failure of 
neuroprotective strategies7 that aim to interrupt or slow the 
injurious postischemic biochemical/molecular events may 
be attributed to various factors, including the heterogeneity 
of clinical stroke populations,8 inadequate sample sizes, and 
dose-limiting drug toxicities. However, recent critiques of the 
preclinical literature have suggested that the discrepancies 
between the preclinical and clinical studies are likely also to 
have arisen from publication bias,9 the limited replication of 
results, and experimental methodological flaws that inflated 
the estimates of effect size and led to the potential selection 
of inappropriate therapeutic candidates.10 A series of Stroke 
Therapy Academic Industry Roundtable (STAIR)11 meet-
ings produced recommendations on the minimum standards 
for preclinical evidence that should, ideally, underpin the 
selection of drug candidates for clinical testing, as well as 
the clinical trial methods. An equivalent process, entitled 
Stem Cells as an Emerging Paradigm in Stroke (STEPS), 
has provided a forum for methodological discussions in the 
cell therapy field.12,13
Overview of stem cell  
therapy in stroke
Stem cells are undifferentiated cells that have the capacity 
to self-renew and differentiate into a range of tissues. Stroke 
therapy has distinct requirements compared with other neuro-
logical diseases, like Parkinson’s disease or multiple sclerosis, 
since stroke is nonprogressive, involves a focal loss of tissue 
of all cell types, and is typically associated with a degree of 
endogenous recovery. Stem cell therapy is not, therefore, 
restricted to a paradigm of the replacement of a tissue, or a 
specific neuronal cell type (the focus in Parkinson’s disease, 
for example), but potentially extends to effects on inflamma-
tion, immunomodulation, and the stimulation of endogenous 
recovery. Cell therapies probably act on multiple mechanisms 
in ischemic stroke, depending upon the timing and mode of 
administration; however, unlike neuroprotectant drugs, cell 
therapies have the advantage that they may be able to respond 
dynamically to an environment that varies both temporally 
and spatially after ischemia, rather than targeting a single 
pathway or mechanism of action. Interaction with the host 
environment appears to dictate the phenotypic properties of 
stem cell grafts. Stem cells come from various sources, and 
although they share some common properties, they also dif-
fer in many respects and behave differently in terms of their 
rate of differentiation, trophic factor secretion, and in their 
stimulation of endogenous processes when in a pathologic 
environment. No studies have compared the different cell 
types in the same experiment.
endogenous stem cells
Until the middle of the 20th century, it was generally believed 
that neurogenesis in the mammalian nervous system was 
restricted to fetal development and that regeneration did 
not occur in the adult brain. In 1965, Altman and Das14 first 
reported postnatal neurogenesis in the rat brain, and by the 
late 20th century, there was evidence of similar endogenous 
neurogenesis in humans.15 In animals and humans, neuro-
blasts are known to be produced in the subventricular zone,16 
subgranular zone of the hippocampal dentate gyrus,17 and, 
albeit controversially, in the newly discovered subcallosal 
zone that lies between the hippocampus and corpus callosum 
in rats.18 Increased neuroblast production following ischemic 
stroke has been observed in the rat subventricular zone, and 
cortical neuroblasts have been reported in both a rat stroke 
model19 and in human brain biopsy specimens of penumbral 
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tissue that were acquired for diagnostic purposes after 
stroke.20,21 Neuroblast production has also been stimulated 
experimentally by extrinsic growth factors, like hepatocyte 
growth factor,22 and specific molecules, such as statins23 
and fluoxetine,24 but few of these neuroblasts appear able to 
migrate to the boundary of ischemic damage,25  calling into 
question their functional relevance − amplifying and sustain-
ing this endogenous poststroke neurogenesis response and 
overcoming the low rate of cell survival may be relevant for 
functional gains. An improved understanding of the role of 
changes in the expression of the developmental genes and 
associated proteins that are observed along the ischemic 
border after stroke26 may also be important in developing cell 
or pharmacologic augmentation therapies that will capitalize 
on endogenous neuroregenerative capacity.
Olfactory ensheathing cells are a self-renewing popu-
lation of cells that display the properties of both glia and 
Schwann cells and are found at the junction between the 
central and peripheral nervous systems. Their main proper-
ties have led them to be studied more in the context of spinal 
cord and nerve root injuries, but their neuroplastic effects 
have been tested in murine models of stroke and they have 
been found to promote neurite outgrowth.27 Few preclinical 
studies exist, and their clinical application remains unclear 
in stroke.28
exogenous stem cells
The application of exogenous cell therapy in neurology began 
with neurodegenerative diseases, for which fetal ventral 
mesencephalic tissue was transplanted with the intention of 
replacement of a specific cell type, such as the dopaminergic 
neurons of the basal ganglia.29 Cell replacement for stroke 
requires the regeneration of multiple functionally specialized 
cell types, with differing ratios in different brain regions, but 
extends also to glial cells and blood vessels since the injury 
involves the entire neurovascular unit.
Neural stem cells
Whether neural stem cells (NSCs) should be defined by their 
tissue of origin or their capacity to generate neural tissue is 
not universally agreed.15 The following discussion consid-
ers the tissue of origin to define NSCs. Cells sourced from 
ectodermal tissue, such as the central nervous system (CNS), 
have restricted differentiation potential and can further be 
categorized into embryonic,30 fetal,31 or adult,30 by origin. 
The use of adult-derived cells does not share the ethical and 
practical concerns of the use of embryonic or fetal cells. Cells 
from adult murine brain have been harvested, expanded in 
culture, and reimplanted as an allogeneic source. Isolated 
cells can be induced to form neurospheres, which are then 
expanded in vitro before delivery via various routes, includ-
ing stereotactic (ST) injection to the brain, and intravenous 
(IV), intra-arterial (IA) and intracerebroventricular (ICV) 
administration. The differentiation spectrum of NSCs is 
restricted to neurons, astrocytes, or oligodendrocytes and can 
be influenced by intrinsic factors,32 such as neuron-restrictive 
silencing factor, and extrinsic factors, such as experimental 
hypoxia33 and epidermal growth factors. The transmission 
of infectious agents by culture media is a concern that can 
be addressed only incompletely by applying strict Good 
Manufacturing Practice standards. Human fetal brain cortex 
cells have been immortalized by the insertion of c-Myc31 
and v-Myc34 transcription factor genes, in order to enhance 
cell survival or allow the regulation of cell replication (for 
example, where c-Myc expression is under the regulatory 
control of a modified estrogen receptor).35 The majority of 
NSC experimental stroke studies have used ST31,36−38 intrac-
erebral delivery, with implantation ranging from hours39 to 
6 weeks38 after stroke. Cell migration to ischemic regions 
has been reported following implantation by ST,38 IV,40 
or IA41 routes. ST-implanted human NSCs have migrated 
up to 1.2 mm in the lesioned hemispheres compared with 
0.2 mm in naïve rat brain.42 Whether more distant migration 
occurs is unclear. Cell survival varies and depends on the 
timing and mode of delivery. Following ST implantation, 
proximity to the lesion influences survival,38 while very few 
cells reach the brain following IV administration as they 
are filtered by the pulmonary vascular bed and sequestered 
in the spleen.43 Slightly greater cell survival in the CNS is 
seen after IA delivery.44 Although many cells die early after 
administration, bioluminescent human NSCs ST-implanted 
7 days after middle cerebral arterial occlusion (MCAo) have 
been observed to survive beyond 2 months, with over 50% 
cell survival confirmed on histology.45 Surviving cells exhibit 
a wide spectrum of fates, ranging from 78% remaining in 
an immature state36 at week 5, to unquantified numbers of 
differentiated neurons forming synapses with host cells.45 
The expression of neuronal cell surface markers does not 
necessarily indicate functioning neuronal tissue, still less, 
useful integration, and the contribution of the surviving 
cells to an observed functional improvement is still unclear. 
A change in neurological or behavioral function has been the 
preferred outcome, rather than infarct volume, as NSC stud-
ies have mostly chosen to implant at subacute time points, 
when infarcts are well-established. A modified neurological 
severity score (NSS), which provides a composite score 
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based on motor, sensory, reflex, and balance responses, has 
been used commonly in preclinical rodent studies to assess 
change, reporting significant improvements compared with 
sham controls, following NSC therapy.46,47 However, a wide 
range of behavioral tests has been employed. The reporting of 
results differs across laboratories,48 and the reproducibility of 
tests across observers and also across time has seldom been 
reported. Despite the lack of clarity regarding the mecha-
nisms of action, NSCs are believed to alter white matter tissue 
structure, and a noninvasive method to measure this would 
be valuable. The effects of NSC treatment on white matter 
reorganization can be monitored by measuring water diffu-
sion49 using magnetic resonance imaging (MRI) with diffu-
sion tensor imaging (DTI) sequences. Although DTI in small 
animals is compromised by the relatively lesser volume of 
white matter present in rodents compared with humans, there 
are also some advantages to use of DTI, including the ability 
to apply longer scan acquisition times and higher magnetic 
field strength. The white matter reorganization observed on 
histology was coincident with improved fractional anisotropy, 
and fiber tracking maps revealed similar orientation patterns 
to that seen on immunohistology.41
Mesenchymal stem cells
Since the first bone marrow-derived mesenchymal stem 
cells (MSCs),50 many other cell types with similar properties 
from various tissues, including bone marrow mononuclear 
cells, adipose-derived stem cells, umbilical cord blood cells 
(UCBCs), endothelial progenitor cells (EPCs), peripheral 
blood progenitor cells, cluster of differentiation (CD)34+ 
cells from placenta, periosteal stem cells, and amniotic fluid 
cells have all been proposed as potential alternatives. The 
relative ease of cell acquisition without ethical difficulties 
has fuelled interest in MSCs, but the specific characteriza-
tion of MSCs has not been consistent over time,51,52 making 
study comparability difficult. In vitro cultures contain a mix 
of committed and noncommitted progenitors that can form, 
not only mesodermal, but under certain circumstances, also 
ectodermal cell types, like neurons, but it is unclear whether 
the MSCs differentiated along neuronal lines in culture will 
have the same properties as do NSCs. Human neuronal 
MSCs, which have the ability to differentiate into neuronal 
cells following transfection of the Notch intracellular 
domain, were ST-implanted 4 days after MCAo in gerbils 
and compared with human MSC. In the human neuronal 
MSC group, better cell survival and functional recovery 
were observed despite the absence of synaptic connection 
between the transplanted and recipient cerebral cells on 
fluorescence-in-situ-hybridization (FISH), suggesting that 
the neuronal differentiation did not contribute to the MSC 
beneficial effects.53 In experiments with MSCs derived from 
donor rats,54 mice,55 rabbit,56 (autologous or allogeneic), 
or humans57 (xenogeneic), cells have been transplanted by 
IV,57 IA,58 ST,59 or intracisternal58 routes into animals, from 
hours57 to 1 month60 after induction of stroke with either 
temporary or permanent MCAo. Homing of the transplanted 
MSCs appears to occur via a complex multistep process that 
includes interactions with the stromal cell-derived factor 1 
(SDF-1) (also called C-X-C motif chemokine 12 [CXCL12]) 
chemokine receptor.61 Homing signals originate from within 
the active inflammatory zone in the injured tissue. MSC 
migration to specific sites has been observed in stroke stud-
ies, where they have been found to travel preferentially to the 
ischemic boundary, following IV57 and ST delivery.62 Few 
cells have been shown to survive in the studies of xenogeneic 
cell implantation. With no immunosuppression, cell survival 
of up to 2 weeks has been reported on ST implantation, but 
the proportion of surviving cells has not been quantified63 
and has qualitatively been described as being a small propor-
tion only. Long-term cell engraftment has not been detected 
with IV administration on histology.64 In another study, out 
of 3×106 MSCs delivered IV, only 3% of administered cells 
expressed neuronal markers in vivo,65 further supporting the 
concept that tissue replacement is not likely to be a function-
ally relevant mechanism of action for this cell type. Trophic 
factors, such as brain-derived neurotrophic factor (BDNF), 
glial-derived neurotrophic factor (GDNF), vascular endothe-
lial growth factor (VEGF), neurotrophin-3 (NT3), fibroblast 
growth factor (FGF), and thrombospondins, secreted by 
the MSCs66,67 in response to the local microenvironment 
may, along with their stimulation of neurogenesis,66 angio-
genesis,68 and immunomodulation,69 underlie functional 
recovery. Astrocytes are known to maintain normal neuronal 
function,70 forming an important pathway for endogenous 
repair.71 Exogenous MSCs have been observed to influence 
astrocyte survival and astrocyte trophic factor gene expres-
sion after anaerobic insult, by upregulating several kinase 
pathways and protein functions.72 After ischemia, astrocytes 
form gliotic scar tissue, which may be helpful in limiting 
tissue inflammation but can impede axonal regeneration. 
IA-implanted MSCs have shown histological evidence of 
improved axon-myelin remodeling after stroke,73 but it is 
unknown whether this mechanism is relevant in other routes 
of MSC administration. MSCs naturally adopt different 
trophic factor expression dependent on the injured host 
neural tissue.74 Higher levels of BDNF, NT3, and VEGF 
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have been detected at the ischemic boundary 14 days after 
ST human MSC transplantation in rat brains compared 
with controls that received saline.75 The expression of 
VEGF and FGF has been consistently high at the ischemic 
boundary, potentially driving endothelial cell proliferation 
and angiogenesis, and facilitating regional blood flow.76 In 
contrast with the NSC studies, infarct volume has been the 
preferred outcome measure for experimental MSC therapy, 
which has been predominantly administered in an acute or 
early subacute IV delivery paradigm, with significant reduc-
tion in infarct volumes and good correlation noted between 
histology and imaging measures.77 Significant improve-
ments have also been reported in behavioral measures, 
which have included assessments of sensorimotor function, 
motor coordination, and placing deficits during locomotion 
(treadmill test),77 forelimb function and placing deficits (limb 
placement test),78 motor coordination and balance (rotarod 
test),75 and a composite of motor, sensory, reflex, and balance 
responses (NSS).79 Other cell types including UCBCs, EPCs, 
adipose-derived stem cells, and hematopoietic progenitor 
cells (CD34+ cells), share some of the properties of bone 
marrow-derived MSCs and have been found to have similar 
effects in animal models. In animal experiments, UCBCs 
respond to ischemic region homing signals, migrate to the 
lesioned hemisphere following IV administration, and dif-
ferentiate, as evidenced by immunohistochemical neuronal 
and astrocytic markers.80 Some MCAo rat studies have 
failed to detect IV-administered UCBC in the lesions despite 
improvement in spontaneous activity and behavioral motor 
tests, suggesting a trophic factor-mediated response.81,82 
CD34+ cells form a significant component of UCBCs that 
have been enriched either from the umbilical cord, periph-
eral blood, or bone marrow, and administered separately. 
IV administration of CD34+ in MCAo models has shown 
ischemic border zone neovascularization that has in turn, 
stimulated endogenous neurogenesis.83 EPCs represent cells 
with varying cell expression markers,84 typically CD34+, 
CD133+, and kinase insert domain receptor (KDR+) (also 
known as vascular endothelial growth factor receptor-2), 
with an angiogenic mechanism of action and found to reduce 
infarct volumes in rat stroke models when administered IV 
a day after MCAo.85 Several Phase I and II MSC clinical 
trials are ongoing (Table 1).
embryonic stem cells
Embryonic stem cells (ESCs) are derived from the first stages 
of embryonic development: the first human ESC lines were 
established in 1998 from the inner cell wall of the blastocyst 
stage.86 Religious and moral objections have been raised to 
the medical use of embryonic material; however, it is not 
widely recognized that the ESCs used for medical research 
are generally obtained from in vitro fertilization programs. 
Media reports often fail to distinguish ESCs from other stem 
cell types, leading to public confusion. ESCs are pluripotent 
and able to differentiate into tissues of all three germ layers. 
Although at first glance this might appear advantageous, 
regulatory control over ESC differentiation may be necessary 
before therapeutic use, since ESCs tend to form teratomas 
when grafted,87 with the postischemic environment possibly 
promoting teratoma formation.88 ESC studies in animal 
stroke models have been concerned with mechanistic aspects 
rather than functional efficacy, and report only isolation, 
neutralization,89 and the electrophysiological activity of dif-
ferentiated neuronal cells.90 Undifferentiated ESCs grafted 
into rat brains have differentiated and integrated with host 
tissues in stroke models,91 showing improved functional out-
comes on the cylinder test, which measures the spontaneous 
use of forelimbs.92
ESCs remain widely researched as a source for in vitro 
generation of neuronal cell lines for drug screening, mecha-
nistic investigation, or therapeutic use. ESCs can be stimulated 
to differentiate into specific neuronal populations or glia, with 
appropriately timed use of growth and inhibitory factors in rel-
evant media and culture conditions. ESCs have been preferen-
tially differentiated to a glutamatergic neuronal phenotype of 
the auditory nerves, with a view to specific tissue regeneration 
of the auditory nerve.93 Similar preferentially differentiated 
cell cultures can be used for in vitro studies, to investigate 
several critical stroke-related molecular processes. Such stud-
ies provide tight experimental control despite limitations of 
their ability to investigate the role of cell interactions. The 
cellular effects of oxygen-glucose deprivation, hypothermia, 
oxidative stress, and excitotoxicity have been modeled with 
chosen degrees of injury, helping to improve our understand-
ing of certain key pathological processes.94
induced pluripotent stem cells
Nobel Laureate Shinya Yamanaka and his colleague Kazutoshi 
Takahashi first demonstrated that differentiated murine cells 
could be reprogrammed to an embryonic-like state, with cells 
having the morphology, growth properties, and cell surface 
markers of ESCs, calling them induced pluripotent stem 
cells (iPSC). Similar iPSCs were later derived from adult 
human somatic cells.95 The Yamanaka method involved the 
transfection of cells with four key nuclear transcription fac-
tors, under ESC culture conditions;96 subsequent studies have 
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identified alternative methods.97 While superficially appealing 
as a means of obtaining ESC-like cells from adult tissue, the 
limited yield of these methods, the potential risks of clini-
cal use of material obtained from viral transfection, and the 
multiple potentially oncogenic transcription factor genes, as 
well as (for stroke) the time required for culture expansion, 
all present significant clinical hurdles that are currently being 
investigated.98 iPSCs can potentially generate autologous 
patient-specific cells, avoiding the ethical, moral, and legal 
issues of ESCs but may share the tumorigenicity issues of 
ESCs.87 The intracerebral implantation of undifferentiated 
iPSCs in a rat MCAo model showed cell expansion to form 
large tridermal teratomas, with little behavioral improvement 
compared with controls, despite differentiated neuroblasts 
and mature neurons being seen in the ischemic lesion.99 
As is the case for ESCs, partial in vitro differentiation may 
be necessary before therapeutic uses can be contemplated. 
A recent study that used human iPSC-derived long-term 
expandable neuroepithelial-like stem cells in a T cell deficient 
rat MCAo model with a 4-month observation period found 
no new tumors or transplant overgrowth, suggesting that 
predifferentiation of iPSCs and the generation of long-term 
self-renewing neural cell lines may offer an effective strategy 
for minimizing the risk for tumor formation.100 The reports of 
improvement in function, reduced infarct volume, and differ-
entiated neuronal cells with electrophysiological properties 
and host synaptic connections following the intracerebral 
implantation of iPSCs derived from human fibroblasts100,101 
are promising, but other studies using ST delivery of iPSCs 
have reported no functional improvement.102
Stem cells and the immune system
Transplanted stem cell survival may be influenced by host 
immune responses, but the transplanted cells may themselves 
modulate the host inflammatory microenvironment after 
stroke. The immunogenicity of allogeneic stem cells varies 
according to the expression of their major histocompatibility 
complex (MHC) I and II and other molecules that stimulate 
host CD8+ or CD4+ T cells.103 MSCs express very few 
MHC antigens, but cell surface marker expression may be 
modified by the host environment, and the lack of in vitro 
immunogenicity may not therefore be informative about the 
potential for problems in clinical use. However, to date, there 
have been no reports of cell-related adverse events or tum-
origenesis following autologous MSC administration in the 
small number of early Phase I clinical trials in stroke104 and 
multiple sclerosis.105 Two clinical trials, of allogeneic NSC106 
(NCT01151124) and MSC107 (NCT01297413) lines for the 
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treatment of stroke with no coadministered immunosuppres-
sion, are currently investigating safety outcomes, including 
clinical, laboratory, and imaging markers. Although there 
is evidence that adult stem cells have an inherent immu-
nologically privileged status and are capable of escaping 
rejection,108 it is unclear whether their MHC expression is 
altered by exposure to proinflammatory cytokines, such as 
occurs in ischemic tissue injury. ST-implanted neural progeni-
tor cells have been observed to have low immunogenicity 
as they are not exposed to systemic immune surveillance, 
but the blood−brain barrier is damaged after stroke and the 
CNS probably does not retain this status. There are sugges-
tions that low immunogenicity could be a unique property 
of NSCs, based on a lack in upregulation of the immuno-
logical response to transplantation of murine NSCs, and 
the lack of difference observed in animals, whether or not 
immunosuppressed, 2 weeks postimplantation and 4 weeks 
post-MCAo.109 Some xenogeneic animal stroke studies have 
coadministered immunosuppressant drugs on the assump-
tion that the recipient species would reject donor cells of 
human origin. Whether or not xenogeneic studies necessitate 
immunosuppression is still unclear. Many studies have not 
reported the use of immunosuppression or have not consid-
ered studying its effects in detail.36,40,45 Immunosuppressant 
drugs have independent neuroprotective effects in animal 
models of stroke, and their use was identified as a significant 
factor in modifying effect size estimates in a meta-analysis 
of animal studies.110
Transplanted stem cells initiate a dynamic sequence of 
host immunomodulatory actions on exposure to the host 
inflammatory microenvironment. They not only integrate 
and differentiate but also home in, extravasate into the 
CNS, and modulate immune responses in situ.111 NSCs are 
reported to show more tropism towards inflammatory sites 
than do MSCs.112 Both NSCs and MSCs exhibit host immune 
modulation in vivo. MSCs release neurotrophic factors, such 
as BDNF, provide trophic support for vulnerable neurons in 
the ischemic penumbra, support endogenous oligodendro-
genesis, and regulate anti-inflammatory responses, leading 
to enhanced tissue sparing.65 NSCs attenuate brain inflam-
mation, modulate microglia activation, limit demyelination, 
and promote host-driven repair.113
Clinical trial design
Ideally, preclinical evidence of efficacy, information on the 
optimal timing and mode of delivery, and toxicity (including 
tumorigenesis and possibly gene silencing studies) should be 
considered in clinical trial planning. The STEPS12,13 meetings 
have suggested essential minimum criteria for the design of 
cell therapy stroke trials, by incorporating general principles 
from the earlier STAIR proposals that primarily concerned 
pharmaceutical development.11 Although these recommend 
that preclinical studies include more than one strain of rodent, 
animals of varying ages, and that there be independent 
confirmation from one or more laboratories, in reality these 
recommendations are rarely followed due to high costs and 
potential commercial restrictions, and preclinical information 
may thus be limited.
The selection of an appropriate target stroke population will 
be influenced by the phase of study, expected mode of action 
of the cell therapy under study, and preclinical data. For studies 
primarily collecting safety data, chronic stroke patients with a 
broad range of severity who are not within the natural recovery 
period are likely to be candidates. The dose of stem cells for 
humans would usually be estimated based on animal studies 
and will need further human testing to define the maximum 
tolerated dose, minimum effective dose, and ideally, a dose-
response curve. For a safety trial, an ascending dose design 
could be incorporated, especially for ST-delivered cells. For 
studies gathering efficacy data, subjects are likely to be in the 
acute or subacute stage after stroke, having deficits that are 
measurable by well-validated clinical scales, and whose natural 
evolution and variability over time after stroke are understood. 
Biomarkers, such as imaging, may offer greater biological 
confidence in the effects of treatment, with sample sizes that 
are smaller than are necessary to distinguish differences in the 
clinical disability scales; imaging markers should correlate 
with clinically relevant measures. For long-term safety fol-
low up, the prevalence of significant comorbidities in stroke 
populations and the intensity of observation in a typically 
disabled and elderly population need to be considered in order 
to minimize trial subject attrition.
Stroke lesion sizes and locations are heterogeneous, and 
there is considerable interindividual variation in the neuro-
anatomical systems involved. Experimental stroke induction 
is a more controlled event, intended to produce a consistent 
lesion size and distribution. Anatomical characterization 
will thus play a significant role in patient selection in tri-
als, not only from the perspective of surgical planning and 
feasibility for studies using delivery by ST implantation, but 
also, more generally as a prognostic marker. For example, 
corticospinal tract integrity predicts motor impairment114 
and the probability of motor recovery.115 Likewise, the tim-
ing of the ST intervention can be challenging in the acute 
stage, when lesion size varies considerably with improving 
edema and anatomical remodeling. While IV delivery is 
more straightforward from this aspect, a persistent occlusion 
of the target artery compromises IA cell delivery and may 
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significantly reduce cell penetration or compromise survival 
at the target site. Timing will also be influenced by knowledge 
of the natural course of recovery and how this aligns with the 
chosen cell’s mechanism of action to maximize effect.
The feasibility of blinding patients and trialists to treat-
ment allocation varies by the treatment delivery route and the 
requirement for placebo controls. Both placebo and blinding 
are relatively easier for IV therapy than for more invasive 
delivery routes since there are procedural complications 
from either IA or direct intracerebral delivery. Whether the 
scientifically rigorous inclusion of placebo controls to permit 
double blinding is sufficiently justified instead of potentially 
less hazardous sham alternatives that could yield a single-blind 
study (for example, a small incision in the groin rather than 
an IA placebo injection, or a scalp incision or burr hole rather 
than an injection of placebo fluid into the brain) may depend 
on the stage of research and the procedural risks. Functional 
change, for example, serial clinical scores or functional brain 
imaging, including both pre- and post-treatment periods, 
may reduce variance. Domain-specific endpoints, as sug-
gested by Cramer et al,116 may be more relevant than broad 
global outcome scales that traverse multiple neural systems; 
at the same time, they may restrict the trial entry criteria to 
those patients with very specific deficits, and thus reduce the 
generalizability of trial results (for example, motor outcome 
endpoints necessitate motor deficits at entry but a positive 
effect may arguably not be applicable to speech deficits).117 
Imaging-based outcomes may help to compare metrics, as 
they could be applied to both humans and animals. The use 
of imaging biomarkers for recovery prediction is promising, 
and these are currently being tested. The major confound of 
providing routine physical rehabilitation treatment in stroke 
recovery trials is an unresolved issue. While some studies of 
therapy inputs for specific clinical problems have identified 
dose-response relationships,118,119 for many routinely applied 
interventions, the efficacy or dose relationship is unknown. 
Even where evidence supports the therapy interventions, few 
clinical services deliver the optimal dose routinely, and there is 
enormous variability across sites and healthcare systems. Since 
animal studies have reported that concomitant specific physical 
rehabilitation may be a prerequisite of stem cell efficacy, this 
represents a major challenge in clinical study design.
Advances and future prospects  
in stem cell therapy for stroke
Many clinical investigations are documented on trials 
databases as planned or underway (Table 1), but the great 
majority of these studies are safety and tolerability studies, 
with small sample sizes and unspecified control groups. 
A wide range of cell types is being investigated, but most 
studies plan autologous bone marrow-derived cell admin-
istration by intravascular routes at subacute time points. 
These studies, if completed, will contribute valuable safety 
data that is a necessary prelude to large-scale efficacy trials, 
but ultimately, large randomized controlled trials with broad 
clinical endpoints will be required to judge the balance of 
risks and benefits.
The genetic modification of stem cells (for example to 
enhance the delivery of trophic factors, like BDNF120 or 
VEGF,121 or to address large scale manufacturing through 
conditional cell immortalization30) may offer advantages for 
allogeneic cell therapies. The allogeneic approaches offer 
the hypothetical advantage of immediate “off the shelf ” 
availability, which is not possible with autologous cells, even 
if cells are not culture-expanded prior to administration. 
Laboratory research into the use of nonviral vectors for 
stable modification of cells, in vivo cell tracking, and the 
modification of stem cell gene expression profiles, is ongo-
ing and will improve our understanding of cell function.122 
Tissue replacement as a therapeutic goal is almost certainly 
beyond the scope of the current therapeutic approaches in 
stroke, but the development of extracellular matrix bioscaf-
folds, to provide structural support for human NSCs, is a 
promising and potentially relevant approach for chronic 
stroke and other forms of brain injury.123 The concept of 
stem cell−secreted extracellular membrane vesicles, provid-
ing extracellular waves of information capable of inducing 
multiple functional responses in adjacent and distant target 
cells, has emerged recently; the relevance of the bidirectional 
genetic information exchange between stem and target cells 
via MSC-secreted extracellular membrane vesicles124 is under 
investigation as a possible means of modifying graft−host 
interactions.
Parallel advances in biomaterial engineering and nano-
technology could provide an inert scaffold for ex-vivo stem 
cell expansion and intracranial delivery,125 and may in future 
address the limitation, for current cell therapy paradigms, of 
the major loss of brain tissue after stroke that leaves only a 
cystic cavity.
Applying novel imaging techniques to monitor stem cell 
effects and identify biomarkers is likely to be the key to 
the neurological application of cell therapies. Conventional 
structural imaging is unlikely to be helpful, but modalities, 
such as motor task fMRI can predict treatment response126 
and provide a measure of the balance of interhemispheric 
control,127 and DTI can provide information on axonal 
integrity, which correlates with functional recovery.128 
Approaches such as resting state fMRI may allow the 
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assessment of the effect of stem cells at a network level on 
either hemisphere.129 Multimodal approaches130 combining 
fMRI and DTI are advancing, and more work with stem 
cell−treated subjects will improve the use of imaging-based 
biomarkers for patient selection, baseline stratification, and 
outcome assessment.
Conclusion
Contrary to long-held beliefs, we now know that the brain 
is highly malleable after an ischemic insult. Endogenous 
neurogenesis, angiogenesis, and synaptogenesis occurs in 
humans, albeit at a rate that is able to provide only partial 
functional recovery in the majority of cases. Cell therapy 
offers a potential for multimodal action that is promising 
within the domain of brain repair therapies. Despite the 
almost certain publication bias in animal stroke studies, stem 
cell experiments have shown evidence of cell migration to 
the lesion, survival, and varying degrees of differentiation. 
Both tissue-specific NSCs and non-tissue-specific MSCs 
have been associated with significantly improved behav-
ioral outcomes. A comprehensive understanding of their 
mechanism of action is lacking, but tissue replacement is 
now believed likely to constitute only a minor contribution 
(if any) to the therapeutic effect. Accordingly, a cell type’s 
capacity to differentiate along specific pathways is likely to 
be a less relevant consideration. The multiple mechanisms 
of action of stem cells include the secretion of trophic fac-
tors, immunomodulation, and anti-inflammatory effects. The 
great majority of the early cell therapy clinical studies have 
involved adult-derived cells of either autologous or allogeneic 
origin, and no major safety issues have been identified to 
date, although the numbers of subjects have been extremely 
small and follow-up periods limited. Several clinical trials 
are ongoing or planned, mostly using MSC cells delivered 
by IV infusion.
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